Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640926 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
A Phase 2 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT00640926 is a Phase 2 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 158 participants.
The verdict
NCT00640926, a Phase 2 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).
Interventions
- DRUG Radezolid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640926
The ClinicalTrials.gov registry entry for NCT00640926 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radezolid is the first listed.
NCT00640926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00640926 about?
NCT00640926 is a clinical study titled "Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia". The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).
What is the current status of trial NCT00640926?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2007-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00640926?
The interventions under investigation include: Radezolid (DRUG).
Who is sponsoring clinical trial NCT00640926?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.